iRGD Peptide
CAY-42319-25 25 mg
Synonyms: cyclic[Cys-Arg-Gly-Asp-Lys-Gly-Pro-Asp-Cys]|Internalizing Arginine-Glycine-Aspartic Acid Peptide
Data Sheet: 
SDS:
SDS:
CAS
1392278-76-0
Formulation
A solid
Purity
≥95%
MW
948,0383
Shipment
-20
Long Term Storage
-20
Shelf Life
1460
Description
A tumor-targeting peptide; has been used in the generation of nanocarriers and LNPs for the delivery of degraders and anticancer agents in vitro and in vivo; ZIF-90 nanocarriers conjugated to iRGD peptide and encapsulating a fluorescent reporter selectively traffic to tumors over kidneys, lungs, spleen, liver, and heart in mice in an MDA-MB-436 mouse xenograft model; ZIF-90 nanocarriers conjugated to iRGD peptide and encapsulating hemin and atovaquone degrade BACH1, reduce the mitochondrial OCR, and induce cell death in MDA-MB-436 cells; the same nanocarriers decrease tumor volume and weight and improve survival in an MDA-MB-436 mouse xenograft model; LNPs conjugated to iRGD peptide and encapsulating mitoxantrone and a pH-responsive DPA polymer reduce tumor weight in an MCF-7 breast cancer mouse xenograft model
ESCLUSIVAMENTE PER USO DI RICERCA (RUO) e non per uso terapeutico o diagnostico su uomini o animali. Il prodotto NON è un Dispositivo Medico o un Diagnostico in Vitro.
PRODUCT FOR RESEARCH USE ONLY (RUO) and not for therapeutic or diagnostic use on humans or animals. The product is NOT a Medical Device or an In-Vitro Diagnostic (IVD).
